\-\ Texto\\:\\ \ \(0\)\
\-\ palpable\\ mass\\ left\\ breast\\ 0800\\.\ \(0\)\
\-\ pt\\ had\\ a\\ left\\ breast\\ mastectomy\\ and\\ sentinel\\ node\\ biopsy\\.sentinel\\ node\\ negative\\;\\ touch\\ prep\\ diagnosis\\ of\\ post\\ mastectomy\\:\\ no\\ metastatic\\ carcinoma\\ identified\\.\ \(0\)\
\-\ \\:\\ routine\\ 2\\-view\\ mammography\\ with\\ palpable\\ mass\\ tagged\\ on\\ left\\ breast\\â\\€\\”breast\\ tissue\\ dense\\,\\ poorly\\ defined\\ 2\\.2cm\\ mass\\ at\\ 0800\\ position\\ in\\ posterior\\ third\\ of\\ left\\ breast\\.\\ no\\ other\\ films\\ for\\ comparison\\.\\ transverse\\/longitudinal\\ us\\â\\€\\”lobulated\\ mass\\ with\\ irregular\\ borders\\ measuring\\ approximately\\ 2\\ x\\ 1cm\\ in\\ size\\.\ \(0\)\
\-\ infiltrating\\ ductal\\ carcinoma\ \(11\)\
\-\ malignancy\\ \\(invasive\\ carcinoma\\ \\(ductal\\/lobular\\)\\,\\ fibroadenoma\\,\\ phyllodes\\ tumor\ \(0\)\
\-\ 39\\ y\\/o\\ female\\ presented\\ with\\ a\\ palpable\\ mass\\ on\\ left\\ breast\\ at\\ 0800\\ position\ \(1\)\
\-\ according\\ to\\ the\\ american\\ cancer\\ society\\ \\,\\ almost\\ 217\\,000\\ new\\ cases\\ of\\ breast\\ cancer\\ will\\ be\\ diagnosed\\ by\\ the\\ end\\ of\\ 2004\\.\\ the\\ most\\ common\\ form\\ of\\ breast\\ cancer\\,\\ accounting\\ for\\ more\\ than\\ 75\\ percent\\ of\\ diagnoses\\,\\ is\\ infiltrating\\ \\(invasive\\)\\ ductal\\ carcinoma\\.\\ this\\ cancer\\ originates\\ within\\ the\\ mammary\\ ducts\\ and\\ penetrates\\ through\\ the\\ ductal\\ walls\\ invading\\ into\\ the\\ surrounding\\ fatty\\ tissue\\ of\\ the\\ breast\\.\\ this\\ 39\\-year\\-old\\ woman\\ found\\ a\\ palpable\\ mass\\ that\\ turned\\ out\\ to\\ be\\ a\\ breast\\ cancer\\.\\ because\\ this\\ patient\\ had\\ fibrocystic\\ changes\\ of\\ her\\ breast\\,\\ the\\ mammogram\\ was\\ not\\ very\\ definitive\\,\\ but\\ the\\ ultrasound\\ was\\ very\\ important\\ in\\ distinguishing\\ the\\ malignancy\\ potential\\ of\\ the\\ mass\\.\\ as\\ an\\ adjunct\\ to\\ mammography\\,\\ ultrasound\\ has\\ become\\ an\\ important\\ tool\\ in\\ evaluating\\ the\\ breast\\ \\.only\\ about\\ 25\\%\\ of\\ breast\\ carcinomas\\ will\\ metastasize\\ to\\ a\\ distant\\ site\\ with\\,\\ unfortunately\\,\\ 95\\%\\ of\\ those\\ patients\\ dying\\ from\\ their\\ metastatic\\ disease\\.\\ metastasis\\ of\\ the\\ breast\\ to\\ varying\\ distant\\ sites\\ is\\ by\\ way\\ of\\ the\\ angiolymphatic\\ system\\,\\ making\\ it\\ very\\ important\\ to\\ monitor\\ lymph\\ nodes\\ and\\ lymphatic\\ ductal\\ invasion\\ on\\ gross\\ specimen\\.\\ axillary\\ lymph\\ nodes\\ are\\ the\\ first\\ nodes\\ seeding\\ with\\ breast\\ carcinoma\\ metastasis\\.\\ for\\ this\\ patient\\,\\ her\\ sentinel\\ lymph\\ node\\ was\\ negative\\.\\ current\\ success\\ rates\\ for\\ the\\ predictive\\ value\\ of\\ sentinel\\ node\\ biopsy\\ are\\ variable\\ with\\ the\\ surgeon\\ performing\\ the\\ procedure\\ and\\ the\\ characteristics\\ of\\ the\\ patient\\ involved\\ \\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ breast\\:\\ 0\\.11642969678919654\ \(0\)\
\-\ sentinel\\:\\ 0\\.05327189545316728\ \(0\)\
\-\ 0800\\:\\ 0\\.050088172863446016\ \(0\)\
\-\ ductal\\:\\ 0\\.04577303046800514\ \(0\)\
\-\ node\\:\\ 0\\.044434586881000784\ \(0\)\
\-\ cancer\\:\\ 0\\.0399029156869995\ \(0\)\
\-\ palpable\\:\\ 0\\.034416148211361255\ \(0\)\
\-\ carcinoma\\:\\ 0\\.03440238167636174\ \(0\)\
\-\ nodes\\:\\ 0\\.032895096872431\ \(0\)\
\-\ important\\:\\ 0\\.032716914899539117\ \(0\)\
\-\ lymph\\:\\ 0\\.029399509167141874\ \(0\)\
\-\ mastectomy\\:\\ 0\\.028851413668654145\ \(0\)\
\-\ distant\\:\\ 0\\.02833452856521252\ \(0\)\
\-\ mammography\\:\\ 0\\.028212334217366138\ \(0\)\
\-\ very\\:\\ 0\\.026435672884577804\ \(0\)\
\-\ infiltrating\\:\\ 0\\.026370063375402618\ \(0\)\
\-\ 0800\\.\\:\\ 0\\.025044086431723008\ \(0\)\
\-\ biopsy\\.sentinel\\:\\ 0\\.025044086431723008\ \(0\)\
\-\ breast\\â\\€\\”breast\\:\\ 0\\.025044086431723008\ \(0\)\
\-\ transverse\\/longitudinal\\:\\ 0\\.025044086431723008\ \(0\)\
\-\ us\\â\\€\\”lobulated\\:\\ 0\\.025044086431723008\ \(0\)\
\-\ ductal\\/lobular\\:\\ 0\\.025044086431723008\ \(0\)\
\-\ 217\\,000\\:\\ 0\\.025044086431723008\ \(0\)\
\-\ \\.only\\:\\ 0\\.025044086431723008\ \(0\)\
\-\ angiolymphatic\\:\\ 0\\.025044086431723008\ \(0\)\
\-\ invasive\\:\\ 0\\.024396192312031013\ \(0\)\
\-\ mass\\:\\ 0\\.023634167751798156\ \(0\)\
\-\ 2\\-view\\:\\ 0\\.023074918305132253\ \(0\)\
\-\ penetrates\\:\\ 0\\.023074918305132253\ \(0\)\
\-\ phyllodes\\:\\ 0\\.021923028793461332\ \(0\)\
\-\ dying\\:\\ 0\\.0211057501785415\ \(0\)\
\-\ 2\\.2cm\\:\\ 0\\.02047181963503522\ \(0\)\
\-\ 39\\-year\\-old\\:\\ 0\\.02047181963503522\ \(0\)\
\-\ position\\:\\ 0\\.02021604006783362\ \(0\)\
\-\ prep\\:\\ 0\\.019953860666870576\ \(0\)\
\-\ malignancy\\:\\ 0\\.018761873169326794\ \(0\)\
\-\ tool\\:\\ 0\\.01850265150844447\ \(0\)\
\-\ seeding\\:\\ 0\\.01823188395218218\ \(0\)\
\-\ metastasis\\:\\ 0\\.01817470071761322\ \(0\)\
\-\ fibrocystic\\:\\ 0\\.017984692540279824\ \(0\)\
\-\ predictive\\:\\ 0\\.017984692540279824\ \(0\)\
\-\ 2004\\.\\:\\ 0\\.017757298484389096\ \(0\)\
\-\ adjunct\\:\\ 0\\.017757298484389096\ \(0\)\
\-\ tagged\\:\\ 0\\.017350761996773545\ \(0\)\
\-\ society\\:\\ 0\\.017350761996773545\ \(0\)\
\-\ mammary\\:\\ 0\\.017167413925359993\ \(0\)\
\-\ turned\\:\\ 0\\.017167413925359993\ \(0\)\
\-\ metastasize\\:\\ 0\\.017167413925359993\ \(0\)\
\-\ distinguishing\\:\\ 0\\.016995184886108756\ \(0\)\
\-\ accounting\\:\\ 0\\.016533483381853713\ \(0\)\
\-\ originates\\:\\ 0\\.016533483381853713\ \(0\)\
\-\ invading\\:\\ 0\\.016136432409197012\ \(0\)\
\-\ lymphatic\\:\\ 0\\.016136432409197012\ \(0\)\
\-\ carcinomas\\:\\ 0\\.015577596345997995\ \(0\)\
\-\ performing\\:\\ 0\\.01547790509653416\ \(0\)\
\-\ fibroadenoma\\:\\ 0\\.015381593870182791\ \(0\)\
\-\ will\\:\\ 0\\.015190233058972397\ \(0\)\
\-\ 1cm\\:\\ 0\\.015110826313920505\ \(0\)\
\-\ success\\:\\ 0\\.01478579690716555\ \(0\)\
\-\ her\\:\\ 0\\.014598929877755316\ \(0\)\
\-\ specimen\\:\\ 0\\.01456431525526296\ \(0\)\
\-\ negative\\:\\ 0\\.014500682735084513\ \(0\)\
\-\ ultrasound\\:\\ 0\\.014404105596626724\ \(0\)\
\-\ diagnoses\\:\\ 0\\.01435885883032084\ \(0\)\
\-\ varying\\:\\ 0\\.014229704358511872\ \(0\)\
\-\ way\\:\\ 0\\.014229704358511872\ \(0\)\
\-\ rates\\:\\ 0\\.014106167108683069\ \(0\)\
\-\ ducts\\:\\ 0\\.013930384711756682\ \(0\)\
\-\ unfortunately\\:\\ 0\\.013930384711756682\ \(0\)\
\-\ monitor\\:\\ 0\\.013818962231207587\ \(0\)\
\-\ value\\:\\ 0\\.013764848040949934\ \(0\)\
\-\ 95\\:\\ 0\\.013659617155494396\ \(0\)\
\-\ left\\:\\ 0\\.013581040756717538\ \(0\)\
\-\ borders\\:\\ 0\\.013508736969943407\ \(0\)\
\-\ according\\:\\ 0\\.013508736969943407\ \(0\)\
\-\ evaluating\\:\\ 0\\.013508736969943407\ \(0\)\
\-\ making\\:\\ 0\\.01346017323880903\ \(0\)\
\-\ percent\\:\\ 0\\.013229077672178484\ \(0\)\
\-\ sites\\:\\ 0\\.013229077672178484\ \(0\)\
\-\ axillary\\:\\ 0\\.013185031687701309\ \(0\)\
\-\ touch\\:\\ 0\\.013098936944816853\ \(0\)\
\-\ variable\\:\\ 0\\.012934200417401088\ \(0\)\
\-\ surgeon\\:\\ 0\\.012934200417401088\ \(0\)\
\-\ mammogram\\:\\ 0\\.012667072719536666\ \(0\)\
\-\ comparison\\:\\ 0\\.01263088230539624\ \(0\)\
\-\ fatty\\:\\ 0\\.012595147128672206\ \(0\)\
\-\ 75\\:\\ 0\\.01242291808942097\ \(0\)\
\-\ walls\\:\\ 0\\.012389690703730086\ \(0\)\
\-\ end\\:\\ 0\\.01232437957240992\ \(0\)\
\-\ metastatic\\:\\ 0\\.012222212520545967\ \(0\)\
\-\ characteristics\\:\\ 0\\.012077188160507563\ \(0\)\
\-\ definitive\\:\\ 0\\.01198976867565883\ \(0\)\
\-\ poorly\\:\\ 0\\.011849794104616835\ \(0\)\
\-\ almost\\:\\ 0\\.011742577263756474\ \(0\)\
\-\ potential\\:\\ 0\\.011690449028903642\ \(0\)\
\-\ invasion\\:\\ 0\\.011690449028903642\ \(0\)\
\-\ american\\:\\ 0\\.011564165612509229\ \(0\)\
\-\ become\\:\\ 0\\.011564165612509229\ \(0\)\
\-\ gross\\:\\ 0\\.011564165612509229\ \(0\)\
\-\ tissue\\:\\ 0\\.011508074934389738\ \(0\)\
\-\ dense\\:\\ 0\\.011467031053565252\ \(0\)\
\-\ current\\:\\ 0\\.011373108149415001\ \(0\)\
\-\ form\\:\\ 0\\.01135010471125415\ \(0\)\
\-\ \\%\\:\\ 0\\.011325687689465952\ \(0\)\
\-\ 39\\:\\ 0\\.011282191299738373\ \(0\)\
\-\ those\\:\\ 0\\.011046206644344584\ \(0\)\
\-\ this\\:\\ 0\\.010922013787660603\ \(0\)\
\-\ their\\:\\ 0\\.010625979002081452\ \(0\)\
\-\ had\\:\\ 0\\.010476419427504024\ \(0\)\
\-\ site\\:\\ 0\\.010259976525254838\ \(0\)\
\-\ defined\\:\\ 0\\.01022892802942475\ \(0\)\
\-\ involved\\:\\ 0\\.01018298240656793\ \(0\)\
\-\ procedure\\:\\ 0\\.01016783085550156\ \(0\)\
\-\ films\\:\\ 0\\.010020600549068077\ \(0\)\
\-\ \\,\\:\\ 0\\.009997814919672545\ \(0\)\
\-\ 25\\:\\ 0\\.009813142779139411\ \(0\)\
\-\ routine\\:\\ 0\\.00973422356292613\ \(0\)\
\-\ third\\:\\ 0\\.00973422356292613\ \(0\)\
\-\ measuring\\:\\ 0\\.009708396938774845\ \(0\)\
\-\ irregular\\:\\ 0\\.009682802990074941\ \(0\)\
\-\ system\\:\\ 0\\.009558181734093176\ \(0\)\
\-\ about\\:\\ 0\\.009358117915068898\ \(0\)\
\-\ pt\\:\\ 0\\.009026033393843048\ \(0\)\
\-\ diagnosed\\:\\ 0\\.008926690786349448\ \(0\)\
\-\ identified\\:\\ 0\\.008674622276097504\ \(0\)\
\-\ biopsy\\:\\ 0\\.008612764891013525\ \(0\)\
\-\ because\\:\\ 0\\.008492949763028546\ \(0\)\
\-\ new\\:\\ 0\\.008459624934092495\ \(0\)\
\-\ was\\:\\ 0\\.00842281979159392\ \(0\)\
\-\ for\\:\\ 0\\.008285319870939944\ \(0\)\
\-\ first\\:\\ 0\\.008146259757914352\ \(0\)\
\-\ size\\:\\ 0\\.008138851907326055\ \(0\)\
\-\ cases\\:\\ 0\\.008087530863582763\ \(0\)\
\-\ by\\:\\ 0\\.008084493768436788\ \(0\)\
\-\ out\\:\\ 0\\.00802288033198442\ \(0\)\
\-\ x\\:\\ 0\\.008008711179964424\ \(0\)\
\-\ surrounding\\:\\ 0\\.007980583137399902\ \(0\)\
\-\ the\\:\\ 0\\.007855072994524193\ \(0\)\
\-\ found\\:\\ 0\\.007650640950148046\ \(0\)\
\-\ post\\:\\ 0\\.007644417707591744\ \(0\)\
\-\ approximately\\:\\ 0\\.00751084609816927\ \(0\)\
\-\ be\\:\\ 0\\.0074872541099086885\ \(0\)\
\-\ patient\\:\\ 0\\.007300499411219215\ \(0\)\
\-\ to\\:\\ 0\\.007279570030278174\ \(0\)\
\-\ changes\\:\\ 0\\.0069575226597586946\ \(0\)\
\-\ through\\:\\ 0\\.0068947642568774675\ \(0\)\
\-\ y\\/o\\:\\ 0\\.006723377925623979\ \(0\)\
\-\ an\\:\\ 0\\.0067140049107086925\ \(0\)\
\-\ are\\:\\ 0\\.006618601548463646\ \(0\)\
\-\ presented\\:\\ 0\\.006617493281313663\ \(0\)\
\-\ at\\:\\ 0\\.006578199731997915\ \(0\)\
\-\ \\:\\:\\ 0\\.006422015999946961\ \(0\)\
\-\ than\\:\\ 0\\.006360934246926914\ \(0\)\
\-\ common\\:\\ 0\\.006353031852148855\ \(0\)\
\-\ patients\\:\\ 0\\.006282882384562574\ \(0\)\
\-\ on\\:\\ 0\\.006169525673568989\ \(0\)\
\-\ \\(\\:\\ 0\\.006156491985032902\ \(0\)\
\-\ more\\:\\ 0\\.006071523606000473\ \(0\)\
\-\ into\\:\\ 0\\.005776495363521894\ \(0\)\
\-\ \\;\\:\\ 0\\.005754037467194869\ \(0\)\
\-\ tumor\\:\\ 0\\.0056597508568488955\ \(0\)\
\-\ a\\:\\ 0\\.005633519912196041\ \(0\)\
\-\ woman\\:\\ 0\\.005607678828093484\ \(0\)\
\-\ most\\:\\ 0\\.005604645289000216\ \(0\)\
\-\ posterior\\:\\ 0\\.005595564058813775\ \(0\)\
\-\ other\\:\\ 0\\.005595564058813775\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0055744867351716475\ \(0\)\
\-\ it\\:\\ 0\\.005456955637877888\ \(0\)\
\-\ 2\\:\\ 0\\.0052275695923595066\ \(0\)\
\-\ but\\:\\ 0\\.005177566196118004\ \(0\)\
\-\ female\\:\\ 0\\.004990796225704073\ \(0\)\
\-\ of\\:\\ 0\\.004964650602187007\ \(0\)\
\-\ no\\:\\ 0\\.004888887219907966\ \(0\)\
\-\ in\\:\\ 0\\.004788604887957443\ \(0\)\
\-\ within\\:\\ 0\\.004631055137460459\ \(0\)\
\-\ has\\:\\ 0\\.004558806734358744\ \(0\)\
\-\ that\\:\\ 0\\.004193127069769384\ \(0\)\
\-\ \\)\\:\\ 0\\.004054191432461961\ \(0\)\
\-\ disease\\:\\ 0\\.003968004378453705\ \(0\)\
\-\ as\\:\\ 0\\.003672095187199227\ \(0\)\
\-\ from\\:\\ 0\\.0035978287305517397\ \(0\)\
\-\ not\\:\\ 0\\.003508007590175953\ \(0\)\
\-\ is\\:\\ 0\\.003194833968095032\ \(0\)\
\-\ and\\:\\ 0\\.0020455568833206645\ \(0\)\
\-\ with\\:\\ 0\\.0019943893651685747\ \(0\)\
\-\ \\.\\:\\ 0\\.001311062412686084\ \(0\)\
